Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
15 October 1997Website:
http://palatin.comNext earnings report:
14 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 29 min agoDividend
Analysts recommendations
Institutional Ownership
PTN Latest News
CRANBURY, N.J. , June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a warrant inducement agreement with an institutional investor to exercise certain outstanding warrants that the Company issued in November 2022 and October 2023 totaling 3,233,277 shares of the Company's common stock for gross proceeds of approximately $6.1 million.
Palatin Technologies (PTN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Late-stage study results indicate that Palatin's (PTN) experimental drug for dry eye disease demonstrated significant and meaningful improvements in various symptoms.
Palatin Technologies, Inc. (NYSE:PTN ) Q4 2023 Earnings Conference Call September 28, 2023 11:00 AM ET Company Participants Carl Spana - President and Chief Executive Officer Steve Wills - Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co., LLC Michael Higgins - Ladenburg Thalmann & Co. Inc. Operator Greetings, and welcome to Palatin's Fourth Quarter and Fiscal Year End 2023 Operating Results Conference Call.
Palatin Technologies, Inc. (PTN) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.75 per share a year ago.
What type of business is Palatin Technologies?
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
What sector is Palatin Technologies in?
Palatin Technologies is in the Healthcare sector
What industry is Palatin Technologies in?
Palatin Technologies is in the Biotechnology industry
What country is Palatin Technologies from?
Palatin Technologies is headquartered in United States
When did Palatin Technologies go public?
Palatin Technologies initial public offering (IPO) was on 15 October 1997
What is Palatin Technologies website?
https://palatin.com
Is Palatin Technologies in the S&P 500?
No, Palatin Technologies is not included in the S&P 500 index
Is Palatin Technologies in the NASDAQ 100?
No, Palatin Technologies is not included in the NASDAQ 100 index
Is Palatin Technologies in the Dow Jones?
No, Palatin Technologies is not included in the Dow Jones index
When does Palatin Technologies report earnings?
The next expected earnings date for Palatin Technologies is 14 November 2024